GIST adjuvant therapy-some answers and more questions

被引：0
|
作者：
Eisenberg, Burton [1 ]
机构：
[1] Dartmouth Hitchcock Med Ctr, Dartmouth Med Sch, Lebanon, NH 03756 USA
来源：
NATURE REVIEWS CLINICAL ONCOLOGY | 2009年 / 6卷 / 08期
关键词：
GASTROINTESTINAL STROMAL TUMORS; IMATINIB MESYLATE; DOSE IMATINIB; TRIAL; KIT;
D O I：
10.1038/nrclinonc.2009.104
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Imatinib is known to be effective in the first-line treatment of metastatic gastrointestinal stromal tumors. a randomized, placebo-controlled trial has now shown that imatinib is safe and improves recurrence-free survival when used as adjuvant therapy after surgical resection of a primary gastrointestinal stromal tumor.
引用
收藏
页码：441 / 442
页数：3
相关论文
共 50 条
12345